How Unethical Research Seeds Medical Mistrust

The recent announcement of a $1.6 million research grant funded by the U.S. Centers for Disease Control and Prevention (CDC) alongside the Pershing Square Foundation and the Bluebell Foundation to a Danish research group affiliated with the Bandim Health Project should set off alarm bells for anyone familiar with both the science and the ethics of vaccine research.

According to the study’s own description, the investigators plan to initiate a randomized controlled trial of the hepatitis B vaccine at birth in Guinea-Bissau beginning in early 2026. The rationale hinges on what they describe as a “unique window of opportunity.” Guinea-Bissau’s Ministry of Health has decided to implement a universal hepatitis B birth-dose policy starting in 2027. Until then, newborns will be randomized to receive the hepatitis B vaccine at birth, the future policy or to receive no hepatitis B vaccine at birth, reflecting the current policy. All infants, regardless of allocation, will receive BCG and oral polio vaccine. Children will then be followed for “overall health outcomes.”

Guinea-Bissau is a small West African country with exceptionally high maternal and infant mortality and an extraordinarily high burden of hepatitis B infection nearly one in five people are infected. In that context, the core ethical problem is already clear: there is no clinical equipoise for the research question being proposed.

The evidence supporting the hepatitis B birth dose is robust and unequivocal. Administered within 24 hours of birth, it prevents perinatal transmission, reduces progression to chronic infection, and lowers the lifetime risk of cirrhosis and hepatocellular carcinoma. It is a cornerstone of the World Health Organization’s global hepatitis B elimination strategy. This is not a hypothesis in need of testing.

Yet this trial is explicitly not designed to evaluate whether the birth dose prevents hepatitis B that question has been answered repeatedly through randomized trials, decades of post-licensure surveillance, and real-world implementation across multiple regions. Instead, the investigators seem to argue that the hepatitis B vaccine at birth has “never been tested on a large scale for its overall health effects,” and that it is therefore unknown whether the vaccine has so-called non-specific effects on all-cause morbidity or mortality.

On that basis, newborns in a high-burden setting will be deliberately randomized to forgo a proven, life-saving intervention not because of supply shortages or parental refusal, but by design to explore speculative population-level effects that are tangential to the vaccine’s known and established purpose.

In high-burden settings like Guinea-Bissau, the hepatitis B birth dose is among the most powerful and cost-effective public health interventions available. The reason it is not universally administered today is not scientific uncertainty, but structural, logistical, and financial barriers which make it challenging for resource-constrained settings to fund this intervention. Those barriers should be the focus of investment. The trial’s ethical justification rests heavily on the claim that infants randomized to no birth dose are merely receiving the “current policy.” That framing is doing substantial ethical work because the absence of a birth-dose policy reflects implementation failure and not uncertainty about benefit. The investigators themselves acknowledge this by noting that Guinea-Bissau has already committed to adopting universal birth-dose vaccination in 2027. That decision alone eliminates any claim of equipoise.

Ethical research depends on genuine uncertainty about whether an intervention is beneficial. That condition is plainly absent here. Randomizing newborns to no hepatitis B vaccine at birth in order to evaluate “overall health effects” of an intervention whose primary benefit is already known is indefensible. When benefit is established, withholding an intervention is no longer neutral experimentation it becomes premeditated harm. This is not a theoretical concern for this trial, the control arm will include infants who remain susceptible to perinatal hepatitis B infection during the highest-risk period of their lives, in a country with limited access to downstream diagnostic and treatment infrastructure. There is no indication that the investigators will assume responsibility for providing lifelong care to children who develop chronic hepatitis B or its downstream complications as a result of being randomized to the control arm. The ethical breach is compounded by where and in whom this study is being conducted.

A randomized trial withholding a proven, life-saving intervention from newborns would not be approved by an institutional review board in the United States or Europe. Ethical standards do not become optional because the participants are African. African children deserve the same protections as children anywhere else. The investigators emphasize that the trial was approved by the Guinean National Ethics Committee in November 2025 and describe it as “the first and likely the only one of its kind.” That doesn't reassure me. Being the only trial of its kind is not a virtue when the reason such trials do not exist elsewhere is because they are considered unethical.

But the danger of this study does not end with the children enrolled. As someone who studies vaccine hesitancy and health misinformation in Africa, I know that mistrust is shaped by history, memory, and lived experience. Narratives about “Africans being used for medical experimentation” or “vaccines being designed to harm African children” are not fringe beliefs. They are persistent, powerful drivers of vaccine refusal impacting the uptake of life-saving vaccines across the continent. These narratives are reinforced every time researchers behave as though ethical shortcuts are acceptable in low-income settings.

We have seen this before. In 1996, Nigeria faced one of the worst meningitis epidemics in its history. While Doctors Without Borders treated children with a WHO-endorsed antibiotic, Pfizer used the crisis as an opportunity to test an experimental drug, Trovan, in children despite limited pediatric safety data and unresolved concerns from adult trials. Parents later reported they had not been informed that their children were receiving an experimental drug. Children died. Others were left with permanent disabilities. Subsequent investigations found that the trial violated fundamental ethical standards, including informed consent. Pfizer eventually settled lawsuits years later, but the damage was already done. The episode became embedded in collective memory as proof that Western medical institutions were willing to experiment on African children during moments of crisis.

That memory had long-lasting consequences. In 2003, polio vaccination campaigns were boycotted across several northern Nigerian states. Religious leaders explicitly cited the Pfizer trial as justification for distrust. Polio cases surged, Nigeria became a reservoir for poliovirus, and global eradication efforts were set back by more than a decade. Rigorous analyses later showed declines not only in polio vaccination but also in routine childhood immunizations particularly among educated mothers who were most aware of the trial.

The proposed hepatitis B birth-dose trial risks repeating this exact pattern. It will not advance science, the scientific question has already been answered. What it will do is provide fresh evidence for long-standing fears of exploitation, hand misinformation a credible narrative, and undermine confidence in vaccines that are already saving millions of lives. Unethical research does not remain confined to academic journals. It reverberates through communities, erodes trust, and produces public health harms that routinely exceed any supposed scientific gain.

If global health institutions and researchers are serious about improving child health in Africa, they must stop repeating the same mistakes under the banner of research. The researchers planning this trial still have an opportunity to do the right thing. Reconsidering a study design that withholds a proven, life-saving intervention from newborns is an ethical obligation. Science advances when we ask hard questions responsibly. It falters when we pursue them especially at the expense of the very children we claim to protect.

African children deserve better.

If you enjoyed reading this piece and value evidence-based analysis, ethical clarity, and accountability in global health, consider subscribing. I write regularly about infectious diseases, vaccines, public health policy, and the real-world consequences of scientific decisions

.